Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

SUNNYVALE, Calif., Feb. 14, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its six and three months ended December 31, 2012. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the six month period ended December 31, 2012 represents a transition period, with the next fiscal year covering the period from January 1, 2013 through December 31, 2013.

Financial Results for the Six and Three Months Ended December 31, 2012 The GAAP (Generally Accepted Accounting Principles) net income for the six months ended December 31, 2012 was $117.5 million, or $1.69 and $1.58 per basic and diluted earnings per share, respectively, compared with GAAP net income of $41.7 million, or $0.61 and $0.58 per basic and diluted earnings per share, respectively, for the six months ended December 31, 2011.

The GAAP net income for the quarter ended December 31, 2012 was $41.9 million, or $0.60 and $0.56 per basic and diluted earnings per share, respectively, compared to GAAP net income of $56.3 million or $0.82 and $0.78 per basic and diluted earnings per share, respectively, for the three months ended December 31, 2011.

The non-GAAP net income reported for the six months ended December 31, 2012 was $125.0 million, or $1.79 and $1.68 income per basic and diluted earnings per share, respectively, compared with non-GAAP net income of $46.3 million, or $0.68 and $0.65 income per basic and diluted earnings per share, respectively for the six months ended December 31, 2011. See "Use of Non-GAAP Financial Measures" below for a description of our Non-GAAP measures. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.

The non-GAAP net income reported for the quarter ended Dece
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research and ... addition of the "Gene Therapy Market, 2015 - ... The "Gene Therapy Market, 2015-2025" report provides an extensive ... lot of research has been carried out in this ... five approved therapies (four available in Asian markets; one ...
(Date:3/3/2015)... BlueInGreen announces the ... sales network. The business venture will bring the ... Atlantic Provinces, exclusively through Resource Systems. , Since ... Canada’s premiere manufacturing representative firms, hosting a diverse ... and wastewater markets. More information on Resource Systems ...
(Date:3/3/2015)... 03, 2015 The winners of awards ... honored by the Global Supply Chain Resiliency Council ... place on Wednesday, February 25th, 2015, at the Hyatt ... formed to bring together supply chain risk management and ... the professional discipline through opportunities to collaborate, develop and ...
(Date:3/3/2015)... , March 3, 2015  Rosa & Co. ... drug-disease modeling and simulation research, today announced it has ... American Society for Clinical Pharmacology and Therapeutics meeting in ... 2015.   Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... will present a poster describing a quantitative systems pharmacology ...
Breaking Biology Technology:Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... JOLLA, Calif., April 2 TorreyPines Therapeutics, Inc. (Nasdaq: ... it received a letter from the Listing Qualifications Department of ... on the Company,s stockholders, equity as reported in its Annual ... 2008, the Company does not comply with the minimum stockholders, ...
... 2 SPO Medical Inc. (OTC: SPOM),a leading developer ... devices, announced today that it has filed its Annual,Report ... 2008. , Gross revenues of ... initial sales of SPO Medical,s finger oximeter PulseOx 6000(TM) ...
... Commission grants marketing authorization for Intercell,s IXIARO, the ... and military personnel in Europe -- This final ... for Human Medicinal Products (CHMP) in December 2008VIENNA, ... announced that its new vaccine to prevent Japanese ...
Cached Biology Technology:TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements 2SPO Medical Files Annual Report for Fiscal 2008 2SPO Medical Files Annual Report for Fiscal 2008 3Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 2Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 3Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 4
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... University scientists have defined a hidden second option plants ... be the first step in boosting plants, nutritional value ... phenylalanine is required to build proteins and is a ... plants, including lignin, which allows plants to stand upright ...
... negative emotions they often use spatial metaphors. A happy person is ... in the dumps. Some researchers believe these metaphors are a clue ... spatial words to talk about emotional states, we also use spatial ... To test this link between vertical space and emotion, in ...
... Human Frontier Science Program Organization (HFSPO) is pleased to ... postdoctoral fellowships, career development awards and research grants. HFSP ... selection in a global competition. The names are available ... HFSP postdoctoral fellowships are given to young scientists ...
Cached Biology News:Second plant pathway could improve nutrition, biofuel production 2To remember the good times, reach for the sky 22010 Human Frontier Science Program awards announced 2
PFM8 Antibody...
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
Component in MasterPure™ Purification Kits...
Biology Products: